During 80th Scientific Sessions of the American Diabetes Association (12-16.06.2020) the scientists from STRATEGMED TREGS consortium and PolTREG company presented for the first time presumptive results of the phase II trial with T regulatory cells. From the tested approaches, the combined treatment with T regulatory cells and antiCD20 antibody proved to be the most promising. The patients treated with this combined scheme were in the clinical remission almost throughout entire 2-year-lasting follow-up, being administered with less than 0.5 units of insulin per kg body weight daily. At the same time, they were characterized by the best metabolic control with glycosylated haemoglobin HbA1c below 6.5%. The patients treated with this combined regimen achieved the longest insulin-independence which lasted as long as 18 months post-treatment.
2020-06-13
June 2020
See other news
2024-09-16
China patent notification boosts PolTREG’s development of Treg cell therapy in multiple sclerosis
2024-09-09
PolTREG Treg cell therapy for patients with type-1 diabetes shows long-term clinical remission and insulin independence
2024-07-24
The European Medicines Agency has granted PolTREG preliminary approval to launch a new Phase 2 clinical trial in presymptomatic Type-1 Diabetes.
2024-06-25
PolTREG will get access to new groups of type-1 diabetes patients with its Treg cellulartherapies after signing a cooperation deal with the University Clinical Center in Gdansk
2024-06-24
Positive results of a long-term safety and efficacy study of PTG-007 in early-onset type-1 diabetes
2024-06-13
PolTREG received approval to operate a genetic engineering facility from Poland’s ministry of Climate and Environment
2024-05-14
PolTREG received a patent in the US protecting the manufacturing of T-regulatory cells to treat Type-1 Diabetes, and ways the therapy is administered